NORTHERN-DATA-AG
16.3.2020 12:43:13 CET | Business Wire | Press release
Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87), one of the largest providers of High-Performance Computing (HPC) solutions worldwide, today announced revenues and earnings forecast for the current financial year 2020.
Following the completion of the successful merger of Northern Data AG and Whinstone US, Inc., Northern Data is now the owner of the world's largest HPC data center currently nearing completion in Texas, US, with an initial capacity of 350 megawatts expected to increase to 1 gigawatt by year-end 2020.
Northern Data has signed binding contracts to provide HPC solutions to global customers, and as such expects significant growth in both total revenues and earnings before interest, taxes, depreciation and amortization (EBITDA). Based on current expectations and in accordance with contracts that have already been signed, the Management Board anticipates revenues of EUR 120 million to EUR 140 million in the course of the financial year 2020. Accordingly, the Management Board expects an EBITDA for the financial year 2020 of between EUR 45 million and EUR 60 million.
This represents a significant increase in comparison to the expected preliminary numbers for Northern Data for 2019 with revenues of around EUR 10 million and a negative EBITDA of around EUR 8 million.
"We have been working on the world's largest HPC data center in Texas for some time and have secured high-quality contracts with global blue-chip customers. We are looking forward to the exciting next step of going live in the coming months," said Aroosh Thillainathan, CEO of Northern Data AG. "Given these recent developments and our state-of-the-art facility in the US, we feel more than confident to deliver this guidance and continue our steep growth path for the years to come."
About Northern Data:
Northern Data AG builds and offers global infrastructure solutions in the field of High-Performance Computing (HPC), offering solutions in the fields of machine learning and artificial intelligence, big data analytics, crypto mining, game streaming and others. Operating internationally the Company evolved from the merger of German Northern Bitcoin AG and American Whinstone US, Inc. and is now a recognized leader in the provision of HPC solutions worldwide. The Company offers HPC solutions, both stationary in large state of the art data centers as well as in mobile containers, which can be located at any location worldwide. In doing so, it combines self-developed software and hardware with intelligent concepts for sustainable energy supply. In Texas, Whinstone is currently building the largest HPC data center in the USA and, at the same time, the world's largest dedicated HPC facility.
Language: |
English |
|
Company: |
Northern Data AG
|
|
Phone: |
+49 69 34 87 52 25 |
|
E-mail: |
||
Internet: |
||
ISIN: |
DE000A0SMU87 |
|
WKN: |
A0SMU8 |
|
Listed: |
Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich (m:access), Tradegate Exchange |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200316005393/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
